JP2017509323A5 - - Google Patents

Download PDF

Info

Publication number
JP2017509323A5
JP2017509323A5 JP2016549449A JP2016549449A JP2017509323A5 JP 2017509323 A5 JP2017509323 A5 JP 2017509323A5 JP 2016549449 A JP2016549449 A JP 2016549449A JP 2016549449 A JP2016549449 A JP 2016549449A JP 2017509323 A5 JP2017509323 A5 JP 2017509323A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
binding molecule
molecule according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016549449A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017509323A (ja
JP6687526B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/052098 external-priority patent/WO2015114150A1/en
Publication of JP2017509323A publication Critical patent/JP2017509323A/ja
Publication of JP2017509323A5 publication Critical patent/JP2017509323A5/ja
Application granted granted Critical
Publication of JP6687526B2 publication Critical patent/JP6687526B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016549449A 2014-02-02 2015-02-02 NGFアンタゴニストドメインおよびTNFαアンタゴニストドメインから構成されるキメラタンパク質 Active JP6687526B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461934828P 2014-02-02 2014-02-02
US61/934,828 2014-02-02
PCT/EP2015/052098 WO2015114150A1 (en) 2014-02-02 2015-02-02 Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020065513A Division JP7074792B2 (ja) 2014-02-02 2020-04-01 NGFアンタゴニストドメインおよびTNFαアンタゴニストドメインから構成されるキメラタンパク質

Publications (3)

Publication Number Publication Date
JP2017509323A JP2017509323A (ja) 2017-04-06
JP2017509323A5 true JP2017509323A5 (OSRAM) 2018-03-08
JP6687526B2 JP6687526B2 (ja) 2020-04-22

Family

ID=52440681

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016549449A Active JP6687526B2 (ja) 2014-02-02 2015-02-02 NGFアンタゴニストドメインおよびTNFαアンタゴニストドメインから構成されるキメラタンパク質
JP2020065513A Active JP7074792B2 (ja) 2014-02-02 2020-04-01 NGFアンタゴニストドメインおよびTNFαアンタゴニストドメインから構成されるキメラタンパク質
JP2022077858A Active JP7520070B2 (ja) 2014-02-02 2022-05-11 NGFアンタゴニストドメインおよびTNFαアンタゴニストドメインから構成されるキメラタンパク質
JP2024109298A Pending JP2024133644A (ja) 2014-02-02 2024-07-08 NGFアンタゴニストドメインおよびTNFαアンタゴニストドメインから構成されるキメラタンパク質

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020065513A Active JP7074792B2 (ja) 2014-02-02 2020-04-01 NGFアンタゴニストドメインおよびTNFαアンタゴニストドメインから構成されるキメラタンパク質
JP2022077858A Active JP7520070B2 (ja) 2014-02-02 2022-05-11 NGFアンタゴニストドメインおよびTNFαアンタゴニストドメインから構成されるキメラタンパク質
JP2024109298A Pending JP2024133644A (ja) 2014-02-02 2024-07-08 NGFアンタゴニストドメインおよびTNFαアンタゴニストドメインから構成されるキメラタンパク質

Country Status (21)

Country Link
US (5) US9884911B2 (OSRAM)
EP (2) EP3696193A1 (OSRAM)
JP (4) JP6687526B2 (OSRAM)
KR (1) KR102489452B1 (OSRAM)
CN (2) CN106459190A (OSRAM)
AU (3) AU2015212787B2 (OSRAM)
CA (1) CA2938066C (OSRAM)
CY (1) CY1123248T1 (OSRAM)
DK (1) DK3099713T3 (OSRAM)
ES (1) ES2784238T3 (OSRAM)
HR (1) HRP20200477T1 (OSRAM)
HU (1) HUE048478T2 (OSRAM)
LT (1) LT3099713T (OSRAM)
MX (1) MX382763B (OSRAM)
PL (1) PL3099713T3 (OSRAM)
PT (1) PT3099713T (OSRAM)
RS (1) RS60156B1 (OSRAM)
RU (1) RU2678810C2 (OSRAM)
SI (1) SI3099713T1 (OSRAM)
SM (1) SMT202000182T1 (OSRAM)
WO (1) WO2015114150A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3696193A1 (en) * 2014-02-02 2020-08-19 MedImmune Limited Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain
US9862760B2 (en) * 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
CN111132997A (zh) 2017-09-21 2020-05-08 默克专利有限公司 包含fgf-18部分的融合蛋白
WO2021142573A1 (zh) * 2020-01-13 2021-07-22 丁邦 一种融合蛋白及其制法和用途
KR20230084199A (ko) * 2020-09-28 2023-06-12 메디뮨 리미티드 통증 치료를 위한 화합물 및 방법
CN114574444B (zh) * 2020-12-01 2024-05-03 达达生物技术(北京)有限公司 自体纤维母细胞在制备抗类风湿关节炎药物中的应用
TWI821881B (zh) * 2021-01-29 2023-11-11 醫研生物科技有限公司 腫瘤壞死因子α重組抗體及其用途
CN116179667A (zh) * 2022-09-21 2023-05-30 福建中妆技术研究有限公司 基于斑马鱼模型中trpv1信号通路筛选皮肤疼痛舒缓原料的试剂盒及应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP1042459A4 (en) * 1997-12-24 2003-07-23 Diatech Pty Ltd BIFUNCTIONAL MOLECULES
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
DE19926068C1 (de) * 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
WO2002096458A1 (en) 2001-05-30 2002-12-05 Genentech, Inc. Anti-ngf antibodies for the treatment of various disorders
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
ES2357948T3 (es) 2002-10-08 2011-05-04 Rinat Neuroscience Corp. Procedimientos para tratar dolor postquirúrgico mediante la administración de un anticuerpo frente al factor de crecimiento nervioso y composiciones que contienen el mismo.
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US20080187954A1 (en) 2004-03-10 2008-08-07 Lonza Ltd. Method For Producing Antibodies
AU2005279347A1 (en) 2004-08-30 2006-03-09 Lonza Biologics Plc. Affinity- plus ion exchange- chromatography for purifying antibodies
EP1846451B1 (en) * 2005-01-24 2013-05-15 Medimmune Limited Human antibodies against human ngf
MX380352B (es) * 2006-06-12 2025-03-12 Aptevo Res & Development Llc Proteinas de union multivalentes monocatenarias con funcion efectora.
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
KR20100021601A (ko) * 2007-05-14 2010-02-25 바이오겐 아이덱 엠에이 인코포레이티드 단일-쇄 Fc(ScFc) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법
WO2009092014A1 (en) 2008-01-18 2009-07-23 Gagnon Peter S Enhanced purification of antibodies and antibody fragments by apatite chromatography
BRPI0913406A2 (pt) 2008-06-03 2018-01-09 Abbott Lab imunoglobulinas de domínio variável duplo e usos das mesmas
US8822645B2 (en) * 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
JP2011016676A (ja) * 2009-07-07 2011-01-27 Sumitomo Electric Ind Ltd 窒化物半導体基板の製造方法
US8716450B2 (en) * 2009-10-15 2014-05-06 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CA2782320A1 (en) 2009-12-02 2011-06-09 Acceleron Pharma Inc. Compositions and methods for increasing serum half-life of fc fusion proteins
KR20130010123A (ko) * 2010-04-07 2013-01-25 아비에 인코포레이티드 TNF-α 결합 단백질
DK2714738T3 (en) * 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
EP2776061B1 (en) 2011-11-07 2019-08-14 MedImmune, LLC Multispecific and multivalent binding proteins and uses thereof
TW201333033A (zh) 2011-12-30 2013-08-16 Abbvie Inc 雙可變域免疫球蛋白及其用途
WO2014106001A2 (en) * 2012-12-28 2014-07-03 Abbvie, Inc. Dual specific binding proteins having a receptor sequence
TW201446800A (zh) 2013-03-15 2014-12-16 Abbvie Inc 針對TNFα之雙特異性結合蛋白
EP3696193A1 (en) 2014-02-02 2020-08-19 MedImmune Limited Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
US20210009671A1 (en) 2019-05-10 2021-01-14 Medimmune Limited Compounds and methods for treating pain

Similar Documents

Publication Publication Date Title
JP2017509323A5 (OSRAM)
CN111518214B (zh) 靶向cldn18.2的双特异性抗体及其制备方法和应用
CA2903595C (en) Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use
CN110305210B (zh) 新型抗体分子、其制备方法及其用途
CN107922486B (zh) 异源二聚体多特异性抗体形式
JP2013515508A5 (OSRAM)
US20170306018A1 (en) Bispecific antibodies against cd3epsilon and ror1
HRP20241775T1 (hr) Bispecifična protutijela koja se specifično vežu na pd1 i lag3
RU2018142544A (ru) Биспецифические связывающие белки и пути их применения
JP2017504578A5 (OSRAM)
JP2010502183A5 (OSRAM)
JP2014158485A5 (OSRAM)
JP2017522891A5 (OSRAM)
IL295295A (en) Antibodies against fcrl5 and methods of their use
JP2005518789A5 (OSRAM)
JP2017520575A5 (OSRAM)
US20210054021A1 (en) Stabilized immunoglobulin domains
JP2019502694A5 (OSRAM)
JP2020524510A5 (OSRAM)
JP2020515277A5 (OSRAM)
JP2020524661A5 (OSRAM)
JP2019535315A5 (OSRAM)
JP2020502233A5 (OSRAM)
JP2021512159A5 (OSRAM)
JP2017534296A5 (OSRAM)